Tags
- 3
- 3–4 defense
- 3 Andromedae
- 4
- A
- Abstract
- Acro
- Across
- Acute
- Acute symptoms
- Adjuvant
- Administration
- Adrenal gland
- Adrenal insufficiency
- Adrenocorticotropic hormone
- Advanced
- Adverse
- Adverse effect
- Adverse event
- Adverse Events
- Adverse reactions
- Agent
- Alive
- Alone
- Alternative
- Ampersand
- An
- Analysis
- Appropriation
- Arm
- AstraZeneca
- Barcelona
- Based on
- Baseline
- Before and After
- Being
- Benefit
- Biological system
- Bladder
- Bladder cancer
- BTC
- Cancer
- Care
- Cause
- Centre
- Chance
- Chemistry
- Chemoradiotherapy
- Chemotherapy
- Cisplatin
- Clinical
- Clinical endpoint
- Clinical manifestation
- Clinical manifestations
- CMV
- Colitis
- Combination
- Combinations
- Combination therapy
- Comparator
- Complete
- Compromise
- Compulsion
- Confidence
- Confidence interval
- Congress
- Consistency
- Consultation
- Contraindication
- Corticosteroid
- Corticosteroid therapy
- Corticotropin-like intermediate peptide
- Creatinine
- Cuts
- Cystectomy
- Cytomegalovirus
- Data
- Death
- Definitive
- Demonstrate
- Demonstration
- Desperately
- Diarrhea
- Discontinuation
- Disease
- Disease progression
- Disorder
- Dose
- Dosing
- Durvalumab
- Effect
- EFS
- Endocrinology
- Endpoint
- England
- Enzyme
- Equivalent
- ESMO
- Estimation
- European
- European Society for Medical Oncology
- Evaluation
- Event-free survival
- Exclude
- Executive
- Fatal
- Field
- Following
- Fourth grade
- Frequency
- Frequently
- Galbraith
- Gastrointestinal perforation
- Gastrointestinal tract
- Grade
- Grade 1
- Grade 2
- Grade 3
- Hazard
- Hazard ratio
- Headache
- Health administration
- Hepatitis
- Hormone
- Hormone replacement therapy
- Hyperthyroidism
- Hypophysitis
- Hypopituitarism
- Hypothyroidism
- If
- Immune disorder
- Immunosuppression
- Immunosuppressive drug
- Immunotherapy
- Incidence
- Include
- Infection
- Infectious
- Initiate
- Initiation
- Insufficiency
- Interim
- Interim analysis
- Interruption
- Interval
- Invasive
- Invasive disease
- Investigator
- Journal
- Journal of Medicine
- Known
- Large intestine
- Less
- Listed
- Liver
- Liver function tests
- Local property
- London
- Mainstay
- Manifestation
- Mass
- Mass Effect
- Maxima and minima
- M.D.
- Median survival
- Medical
- Medicine
- Metástasis
- MIBC
- Monitor
- Muscle-invasive bladder cancer
- Need
- Neoadjuvant therapy
- New
- New England
- Niagara
- No
- Non-small-cell lung carcinoma
- Normal distribution
- Observation
- Oncology
- Organ
- Os Hr
- Over
- Pacific
- Pacific, Washington
- Patient
- Perforation
- Perioperative
- Permanently
- Phase
- Phase III
- Phases of clinical research
- Photophobia
- Placebo
- Planning
- Platinum-based antineoplastic
- Pneumonitis
- Potomac
- Powles
- Precaution
- Precautions
- Prednisone
- Presenting
- Presidential
- Primary
- Principal
- Principal investigator
- Professor
- Profile
- Progression
- Publishing
- Queen Mary University of London
- Radiation
- Radiation-induced lung injury
- Radical
- Reaction
- Recurrence
- Reduction
- Regimen
- Removal
- Remove
- Repeat
- Replacement
- Require
- Research and development
- Result
- Risk
- Safety
- Safety information
- Safety signals
- Secondary
- Secondary adrenal insufficiency
- Settings
- Severity
- Signal
- Signals
- Signs
- Simultaneity
- Single
- Spain
- Specialty
- Specific
- Standard of care
- Statistical significance
- Statistics
- Still
- Strategy
- Studie
- Suffer
- Summary
- Surgery
- Survival
- Survival rate
- Susan Galbraith
- Symposium
- Symptom
- Symptomatic
- Symptomatic treatment
- Symptoms
- Systemic
- Taper
- Tested
- The first
- The Frequency
- The New England Journal of Medicine
- The Niagara
- Therapy
- The standard
- Thoma
- Thomas Powles
- Thorax
- Thyroid
- Thyroid disease
- Thyroiditis
- Tissue
- Today
- Transform
- Treatment of cancer
- Trial
- Twenty Years
- Two percent
- U.K.
- Underlying
- United States Peace Index
- Urinary bladder
- Validate
- Validation
- Versus
- Vice president
- Visual
- Visual field
- Volga
- Warning
- Warnings
- Warnings and precautions
- When
- Who
- Workup